This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan catalyzing enzyme. It has been suggested
that it has a role in lower airway allergic inflammations, but its role in allergic
rhinitis has not been investigated.

Objective

Our aim was to evaluate the expression of IDO in the nasal mucosa of allergic rhinitis
patients allergic to birch pollen during peak exposure to birch pollen allergen and
compare it to non-atopic patients.

Methods

IDO expression was immunohistochemically evaluated from nasal specimens obtained in-
and off-season from otherwise healthy non-smoking volunteers both allergic to birch
pollen (having mild or moderate allergic rhinoconjunctivitis) and non-allergic controls.
Results: The IDO expression levels were low in healthy controls and remained low also in patients
allergic to birch pollen. There were no differences in the expression of IDO in- and
off-season in either healthy or allergic subjects.

Conclusions

There is a controversy in the role of IDO in upper and lower airways during allergic
airway disease. It seems that IDO is associated to allergic inflammations of the lower
airways, but does not have a local role in the nasal cavity at least in mild or moderate
forms of allergic rhinitis.

Keywords:

Introduction

Indoleamine 2,3 dioxygenase (IDO) is an intracellular enzyme that initiates the first
and rate-limiting step of tryptophan breakdown along the kynurenine pathway [1]. IDO is widely expressed in a variety of cell types including leukocytes and tumour
cells [2]. Initially the role of IDO was thought to be mainly antimicrobial by reducing the
availability of the essential amino acid tryptophan in the inflammatory environment
[3]. In the past years, IDO has emerged as an important regulator of the immune system;
however, it is not known whether local IDO activity is beneficial or detrimental to
inflamed tissues. IDO is induced by interferon γ (IFN-γ) and other inflammatory cytokines
during inflammation or as a consequence of normal tissue function [4]. IDO suppresses T cell activity and promotes T cell tolerance to further antigenic
challenges, by promoting the differentiation of naïve CD4 T cells into regulatory
T cells, putatively by regulation by dendritic cells [5-10]. IDO seems to serve as a negative feedback loop or is not essential for Th1 responses,
but plays a distinct role in up-regulating Th2 dominant immune responses [2,11]. Moreover, IDO has also been shown to down-regulate Th2 responses [12]. The role of IDO in the modulation of allergic airway inflammation has recently been
investigated [13-16].

Our objective was to observe IDO expression levels in the nasal mucosa of allergic
rhinitis patients allergic to birch pollen in relation to exposure to birch pollen
allergen and compare it to healthy controls.

Materials and methods

Subjects

This study is a case-control study. It was carried out at the Department of Otorhinolaryngology,
Tampere University Hospital, Finland and has been approved by the Hospital's Ethical
committee. Written informed consent was obtained from all patients. The subjects were
Caucasian. Patients were either atopic with allergic rhinoconjunctivitis symptoms,
or non-atopic. Moreover, the patients did not have other diseases such as asthma.
The diagnosis of birch pollen-induced allergic rhinitis was based on a history of
seasonal allergic rhinitis during spring, clinical examination, and skin prick test
positivity. Characteristics of the subject groups are shown in table 1. Specimens were taken from the nasal cavity. Biopsies from the anterior edge of the
inferior turbinate were obtained with Fokkens' forceps under local anaesthesia. Specimens
were taken during both winter (off season) and during peak allergen exposure in spring
(in season, natural allergen exposure). Patients were not allowed to use their medication
(antihistamine and/or nasal corticosteroids) for a minimum of 5 days before nasal
biopsies were taken.

Sample staining

Nasal specimens were immediately snap-frozen in liquid nitrogen and stored at -80°C
until analysis. Tissue samples were stained with hemalaun-eosin to calculate the number
of mucosal leukocytes and eosinophils/mm2 and to evaluate the inflammation score (0 = no inflammation, 1 = mild, 2 = moderate,
3 = severe inflammation) For light microscope evaluation, immunoperoxidase staining
was used and specimens were cut into 3-5 μm thick frozen sections on Superfrost Plus
microscope slides. (Menzel-Gläser, Braunschweig, Germany). Frozen sections were fixed
with formalin during 45 minutes. Fully automated immunostaining was performed by Ventana
BenchMark LT Automated IHC Stainer (Ventana Medical System, Arizona, USA). Ultraview
Universal DAB detection kit (catalogue No. 760-500, Ventana Medical System, Arizona,
USA) was used. For epitope retrieval CC1: Tris -EDTA buffer pH 8.0 (catalogue No 950-124,
Ventana) was used at 95°C to 100°C for 8 minutes. Endogenous peroxidase was blocked
with UV-Inhibitor 3% H202 (Ventana) for 4 minutes at 37°C. Tissue slides were rinsed
between steps with Ventana Tris-based Reaction buffer (catalogue No. 950-300, Ventana).
Slides were incubated at 37°C for 32 minutes with mAb anti-Indoleamine 2,3 dioxygenase
(1:200, clone MAB5412, Chemicon International Inc., USA) followed by application of
Ventana Ultraview HRP Universal Multimer (8 minutes at 37°C). Diaminobenzidine (DAB)
was used as a chromogen and haematoxylin as a nuclear stain. Known positive tissue
samples (from coeliac or inflammatory bowel disease) were also used to confirm the
staining reliability of all separate staining patches [17,18]. The specificity of immunohistochemistry was controlled by omitting the primary antibodies
or replacing them with irrelevant antisera.

Light microscopic evaluation

Sections were examined with a Leica DM 2000 light microscope (Leica Microsystems GmbH,
Wetzlar, Germany) by two independent observers blinded to the experimental conditions.
In a sample, there was either moderate or strong immunoreactivity of all epithelial
cells or no epithelial positivity at all. Thus, the results were expressed as IDO
positive epithelium or IDO negative epithelium. The percentage of IDO positive mucosal
leukocytes was counted.

Results

IDO was expressed in the vicinity of the Golgi apparatus of epithelial cells, but
not on the supraepithelial mucus. IDO was additionally expressed weakly in submucosal
leukocytes and in intraepithelial glands. When observing the nasal biopsies, the number
of specimens having positive epithelial IDO staining was not associated with atopy
during either winter or spring (P > 0.05 by Fisher's test, Table 1, Figure 1). The percentage of IDO positive leukocytes did not associate with atopy in specimens
taken during either winter or spring (P > 0.05, by Kruskal-Wallis test, Table 2, Figure 1). Nor did it associate with the expression of IDO in the epithelium (P > 0.05, by
Kruskal-Wallis test, data not shown). The subjects did not have changes in the epithelial
IDO expression or in the percentage of IDO positive leukocytes when comparing specimens
taken during winter and spring from the same individuals (P > 0.05, by Wilcoxon test,
Table 2). The median number of mucosal eosinophils was significantly higher in atopic than
in non-atopic subjects only during symptomatic spring (P = 0.044, by Kruskal-Wallis
and Mann Whitney U test, table 2), whereas the percentage of eosinophils did not significantly differ between atopic
and non-atopic subjects (P > 0.05, by Kruskal-Wallis test, table 2). Interestingly, during spring the number of mucosal leukocytes and the percentage
of IDO positive leukocytes correlated significantly (P < 0.05, r = 0.46, by Spearman
rank correlation test, data not shown).

Figure 1.The expression of indoleamine 2,3-dioxygenase (IDO) in biopsies from the nasal cavity. (A) Nasal mucosa taken from a patient with allergic rhinitis off-season (during
winter). No epithelial or leukocyte expression of IDO. (B) Specimen from another patient
with allergic rhinitis, taken off-season, has epithelial IDO+ and leukocyte IDO-. (C) The same allergic rhinitis patient as in frame A, did not display any IDO expression
in the specimen taken in-season (during spring). (D) Specimen from a healthy patient,
taken off-season, shows epithelial IDO- and leukocyte IDO+. Original magnification 200× (A, B, D) and 400× (C).

As expected, atopics had significantly increased serum IgE levels (p < 0,001, by Kruskal-Wallis,
Mann Whitney U). Atopic subjects had a significantly increased median symptom score
during symptomatic spring in comparison to asymptomatic winter (P = 0.031, by Wilcoxon
test, table 2), whereas in the non-atopic subjects, the median symptom score in winter and spring
did not vary (P > 0.05, by Wilcoxon test, table 2). Accordingly, the median symptom score was significantly higher in the atopic than
in the non-atopic group during spring but did not differ during winter (P = 0.003,
P > 0.05, respectively, by Fisher's exact test, table 2).

Discussion

We aimed to evaluate IDO expression in two well defined human phenotypes: controls
and their atopic counter-parts. Skin prick tests (SPT) were performed on all study
subjects to confirm diagnosis. The control and atopic groups did not differ in terms
of patient number, age, sex, peripheral blood eosinophils, percentage of peripheral
blood eosinophils. (p > 0,05 Kruskal-Wallis, Mann Whitney U) In comparison to controls,
atopics had significantly higher serum IgE levels as well as significantly higher
IgE levels against allergens to which the subjects were allergic. Atopics and controls
differed in their symptom score only during the spring (in season, natural allergen
exposure). Surprisingly, there were no differences between inflammation score, leukocyte
numbers, percentages of eosinophils, IDO+ in epithelial cells and leucocytes during
winter (off season) and spring. Atopics had a higher number of eosinophils during
spring only.

We observed that in the nasal cavity, expression of IDO was low and did not differ
between atopic and non-atopic groups. Moreover IDO expression did not fluctuate in
the same individuals between symptomatic spring and asymptomatic winter season. We
have also previously shown that the role of the nasal epithelium in birch pollen atopy
is important [19]. In contrast others have shown that IDO might have a role in atopy. Paveglio et al.
very recently showed in a transgenic mouse model that over-expression of IDO in the
lungs might cause an anti-asthmatic effect by diminishing proliferation, numbers and
cytokine production of CD4 + T cells [20]. Others have also previously shown that after in vivo aeroallergen exposure, serum IDO activity was increased in asymptomatic atopics compared
with either symptomatic atopic or non-atopic individuals [21]. When exposing in vitro monocyte-derived dendritic cells with house dust mite Dermatophagoides pteronyssinus
1, functionally active IDO decreased in cells from patients with house dust mite-sensitive
asthma compared to non-atopic asthmatics [15]. In asthmatic patients, the baseline IDO activity in sputum has been shown to be
significantly lower than control levels, but normal baseline activity in asthmatic
patients could be induced by using inhaled corticosteroids [22]. We have previously demonstrated that a high expression of epithelial and leukocyte
IDO is associated with chronic rhinosinusitis with nasal polyps, while the expression
in chronic rhinosinusitis without nasal polyps remained at the control level [23]. Thus in the upper airways, in contrast to lower airways, it seems that IDO might
have a role in the nasal polyp pathomechanisms instead of atopy. Yet, more studies
are required to bring evidence on this.

The expression of IDO differs between tissues [24]. Recently, two isoforms of IDO have been studied, IDO1 and IDO2. The expression and
activity of both isoform differs in different tissues and in same cell cultures [25]. Both isoforms therefore might differ somehow in their roles [26,27]. Having this in mind, it could be possible that the anti-IDO mAb we used could be
specific only for the IDO1 isotope [27]. Also, in some tissues IDO expression does not correlate with its activity. Indeed,
elevated expression of IDO can translate into little activity or no activity at all
[24]. Even though high levels of IDO expression can be measured, this does not necessarily
translate into activity measured by ratio of tryptophan over kynurenine.

Both atopic asthma and atopic rhinitis are complex diseases with different phenotypes
and genetic backgrounds. Currently it is thought that patients with certain (epi)genetic
elements are prone to have immunological dysfunctions of respiratory barriers putatively
by stimulation by certain environmental interactions [28]. Thus, our findings suggest that adult patients with only birch pollen AR but not
asthma symptoms do not have local IDO. In the future, it would be of interest to observe
whether immunological factors differ in patients having only the AR phenotype compared
to those with the AR and asthma phenotype [29].

Conclusions

This study showed that in the nasal cavity, epithelial and leukocyte IDO expression
is low and is not associated to allergic rhinitis caused by birch pollen. There is
a controversy in the role of IDO in the pathogenesis of atopy, between upper and lower
airways. More human studies are warranted to study the role of IDO in more detail
in allergic rhinitis and other atopies.

Abbreviations

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ST-S designed the study and collected the specimens with ML; TH performed staining.
AL, ST-S, TP, and JK evaluated the specimens. AL and ST-S were involved in the data
interpretation, literature search and writing. All authors commented critically on
the writing. All authors have read and approved the final manuscript.

Acknowledgements

The authors thank Eini Eskola, Raija Hukkila, and Marja-Leena Koskinen for excellent
technical assistance, and research nurse Marja-Leena Oksanen for excellent collaboration.
Last but not least, we thank all the volunteers who participated in the study. This
study was supported by research grants from the Ahokas Foundation, the Competitive
Research Funds of Hospital District of Helsinki and Uusimaa, and Pirkanmaa Hospital
District, the Finnish Anti-Tuberculosis Association, the Finnish Society of Allergology
and Immunology, the Finnish Society of Otorhinolaryngology, the Tampere Tuberculosis
Foundation, and the Väinö and Laina Kivi Foundation.